With An Additional Active Ingredient (excludes Reaction Product Or Complex) Patents (Class 514/154)
-
Publication number: 20110217249Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventor: Frank Dreher
-
Publication number: 20110218139Abstract: A combination therapy for treating a bacterial biofilm comprises a therapeutically effective amount of an antibiotic comprising an aminoglyco side or tetracycline, or a combination of two or more thereof, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm. A method of treating a bacterial biofilm comprising Pseudomonas aeruginosa comprises contacting the bacterial biofilm with a combination therapy comprising a therapeutically effective amount of an antibiotic, and a cationic porphyrin in an amount effective for enhancing the effectiveness of the antibiotic in treating the bacterial biofilm.Type: ApplicationFiled: March 4, 2011Publication date: September 8, 2011Inventors: Jayne Robinson, Tracy Collins
-
Publication number: 20110189125Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.Type: ApplicationFiled: March 18, 2011Publication date: August 4, 2011Applicants: Trustees of the University of Pennsylvania, Fox Chase Cancer CenterInventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy
-
Publication number: 20110189304Abstract: The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency. The compositions preferably comprise a finely powdered, carboxylic acid salt and a liquid block copolymer of ethylene oxide and propylene oxide.Type: ApplicationFiled: April 15, 2011Publication date: August 4, 2011Inventor: Richard L. Kronenthal
-
Publication number: 20110183943Abstract: A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy.Type: ApplicationFiled: May 18, 2009Publication date: July 28, 2011Applicant: GALDERMA RESEARCH & DEVELOPMENTInventors: Jean-Charles Dhuin, Nabil Kerrouche, Stéphanie Arsonnaud, Pascale Soto
-
Publication number: 20110171232Abstract: Disclosed is a method of diagnosing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis an autoimmune disease. Also disclosed is a method of treating these autoimmune diseases, which involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of antimicrobial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. Also disclosed is a kit for the diagnosis or treatment of autoimmune diseases.Type: ApplicationFiled: March 28, 2011Publication date: July 14, 2011Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Henry C. Lin, Mark Pimentel
-
Publication number: 20110171299Abstract: The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline or a physiologically acceptable salt thereof; (ii) admixing a metal salt with the aqueous solution; (iii) admixing a base to increase the pH of the aqueous solution, thereby forming a suspension of doxycycline metal; and (iv) drying the suspension, thereby forming a dry granulation of doxycycline metal complex.Type: ApplicationFiled: December 18, 2008Publication date: July 14, 2011Applicant: Warner Chilcott Company, Inc.Inventors: Tina deVries, Lynn Gold
-
Publication number: 20110171195Abstract: Methods and compositions are provided for treating a urinary tract infection (UTI). The methods involve administering to a subject in need thereof a cAMP elevator or agent that mimics cAMP, particularly a labdane diterpene such as forskolin or a derivative or analog thereof in a therapeutically effective amount to treat a UTI. The methods may further include administration of at least one cAMP elevator in combination with one or more additional active compounds from other classes of therapeutic agents, such as antimicrobial agents or cholesterol lowering drugs. Compositions of the invention include pharmaceutical compositions and kits for treating a UTI in a subject in need thereof that include therapeutically effective amounts of at least two cAMP elevators, particularly where one of the cAMP elevators is a labdane diterpene such as forskolin or a derivative or analog thereof.Type: ApplicationFiled: June 12, 2008Publication date: July 14, 2011Applicant: Duke UniversityInventors: Soman N. Abraham, Brian L. Bishop, Matthew J. Duncan, K. Ranga Rama Krishnan, Jeongmin Song, Guojie Li, David A. Zaas
-
Publication number: 20110144003Abstract: A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide.Type: ApplicationFiled: May 20, 2009Publication date: June 16, 2011Inventors: Jean-Charles Dhuin, Nabil Kerrouche, Stéphanie Arsonnaud, Pascale Soto
-
Publication number: 20110142923Abstract: The present invention relates to ophthalmic pharmaceutical compositions comprising Sorafenib, its derivatives or active metabolites, for the treatment and prevention of ocular neoangiogenic pathologies.Type: ApplicationFiled: August 6, 2009Publication date: June 16, 2011Inventors: Maria Grazia Mazzone, Vincenzo Papa, Francesco Giuliano, Manuela Marrano
-
Publication number: 20110142802Abstract: A fungicidal composition suitable for control of disease caused by phytopathogens comprising (A) a compound of formula (I), wherein R1 is methyl, ethyl or isopropyl; R2 is 2-chloro-6-fluoro-phenyl, 2,4,6-trifluorophenyl or 2,6-difluoro-4-methoxy-phenyl; R3 is chloro, fluoro or methoxy; and (B) a compound selected, for example, from the group consisting of (B1) a strobilurin fungicide, (B2) an azole fungicide, (B3) a morpholine fungicide, and (B4) an anilinopyrimidine fungicide.Type: ApplicationFiled: January 14, 2009Publication date: June 16, 2011Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Jeremy R. Godwin, Stephan Trah, Clemens Lamberth, Raphael Dumeunier, Valeria Grasso, Sebastian Volker Wendeborn
-
Patent number: 7960366Abstract: Methods and compositions for treating for the synergistic treatment of fungal associated disorders are discussed.Type: GrantFiled: September 16, 2004Date of Patent: June 14, 2011Assignee: Paratek Pharmaceuticals, Inc.Inventors: Michael Draper, Mark L. Nelson
-
Patent number: 7959913Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.Type: GrantFiled: March 10, 2008Date of Patent: June 14, 2011Assignee: Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20110123517Abstract: A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device.Type: ApplicationFiled: December 3, 2010Publication date: May 26, 2011Applicant: Medtronic, Inc.Inventors: Genevieve L. Gallagher, Kimberly Chaffin, Zhongping C. Yang
-
Patent number: 7947301Abstract: Anti-infective articles capable of preventing infection associated with implantation of medical devices include low levels of anti-infective agents, may cover only a fraction of the portion of the medical device and be effective, or may rapidly elute anti-infective agent, without sustained elution, and still be effective.Type: GrantFiled: April 17, 2008Date of Patent: May 24, 2011Assignee: Medtronic, Inc.Inventors: Thomas C. Bischoff, William V. Ferris, Jr.
-
Publication number: 20110117197Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.Type: ApplicationFiled: July 14, 2009Publication date: May 19, 2011Applicant: POLYPID LTD.Inventors: Noam Emanuel, Moshe Neuman, Shlomo Barak
-
Patent number: 7943600Abstract: This invention provides methods and pharmaceutical compositions for treating a subject having a condition associated with an antibiotic resistant bacterial infection. The invention includes administering to a subject a therapeutically effective combination of an antibiotic and a toxic compound (e.g., a nucleic acid damaging agent, an alkylating agent, or a heavy metal containing compound).Type: GrantFiled: December 20, 2005Date of Patent: May 17, 2011Assignees: Massachusetts Institute of Technology, University of MassachusettsInventors: Doriana Froim, John M. Essigmann, Martin G. Marinus
-
Publication number: 20110110939Abstract: The present invention features methods and kits that utilize Ang-2 antagonists for the treatment, inhibition, and prevention of a systemic anthrax infection. The invention described herein also features methods for the diagnosis of a systemic anthrax infection by detecting elevated levels of Ang-2 in the serum of a subject.Type: ApplicationFiled: March 23, 2009Publication date: May 12, 2011Inventor: Samir M. Parikh
-
Publication number: 20110111057Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.Type: ApplicationFiled: October 7, 2010Publication date: May 12, 2011Inventors: John C. Reed, Maurizio Pellecchia
-
Publication number: 20110098255Abstract: The primary subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination in the treatment of pathological conditions related to PARP activation and/or that could benefit from Akt activation. A further subject of the invention is the use of a PARP inhibitor and an Akt kinase activating compound in combination for the preparation of pharmaceutical composition or kit for the treatment of a pathological condition related to PARP activation. The invention also relates to pharmaceutical composition, which contains a PARP-inhibitor and an Akt kinase activating compound together with auxiliaries generally used in pharmacy.Type: ApplicationFiled: July 1, 2009Publication date: April 28, 2011Inventors: Ferenc Gallyas, Balázs Sümegi, Sára Vetö, Péter Ács, Sámuel Komoly, Zsolt Illés
-
Publication number: 20110086797Abstract: Provided are compositions and methods for treating bacterial infections. It is demonstrated herein that bacteria cell wall materials stimulate germination of spores of Gram-positive bacteria, and that such activity requires Ser/Thr kinase PrkC. By modulating one or both, spores (which can be antibiotic resistant) can be stimulated or inhibited from germination, which can be exploited in various methods of therapeutic treatment. Also provided is a method of modulating germination of a spore of a Gram-positive bacterium. Also provided is a method of decontaminating an environment.Type: ApplicationFiled: March 26, 2010Publication date: April 14, 2011Applicant: The Trustees of Columbia University in the City of New YorkInventor: Jonathan Dworkin
-
Patent number: 7910135Abstract: The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: ULURU Inc.Inventors: John St. John, Daniel G. Moro
-
Publication number: 20110059917Abstract: The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.Type: ApplicationFiled: August 10, 2010Publication date: March 10, 2011Inventors: Joaquin Jimenez, Niven Rajin Narain, John Patrick McCook
-
Publication number: 20110059925Abstract: The present invention provides a mucoadhesive broad spectrum antibiotic with anti-inflammatory characteristics with strong tissue penetration for improving lid margin function and the treatment of diseases associated therewith. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of blepharitis and dry eye disease.Type: ApplicationFiled: March 26, 2009Publication date: March 10, 2011Inventor: Eric Donnenfeld
-
Publication number: 20110052613Abstract: Provided is a method of increasing the stability of wild-type ?-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of ?-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for ?-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding ?-glucocerebrosidase. Further provided are ?-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of ?-glucocerebrosidase in vivo in the central nervous system.Type: ApplicationFiled: November 8, 2010Publication date: March 3, 2011Applicant: AMICUS THERAPEUTICS, INC.Inventor: Brandon Alan Wustman
-
Patent number: 7897591Abstract: The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.Type: GrantFiled: July 28, 2006Date of Patent: March 1, 2011Assignee: Children's Medical Center CorporationInventors: Mark Puder, Marsha A. Moses
-
Publication number: 20110039806Abstract: The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline.Type: ApplicationFiled: October 18, 2007Publication date: February 17, 2011Inventors: Shlomo Mendlovic, Yechiel Levkovitz
-
Publication number: 20110033402Abstract: The invention relates to a novel solubilized small molecule topical formulation for the transdermal delivery of small molecule agents comprising: a small molecule agent, one or more micelle forming compounds, one or more skin penetration enhancers, a surfactant, and one or more solvents, wherein the small molecule agent is solubilized in the solvent. The invention further relates to the use of the topical formulation as well as the process for making the topical formulation.Type: ApplicationFiled: June 29, 2010Publication date: February 10, 2011Inventor: Pankaj Modi
-
Publication number: 20110028407Abstract: The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds.Type: ApplicationFiled: February 8, 2008Publication date: February 3, 2011Inventors: Mark A. Jutila, Kirk J. Lubick
-
Patent number: 7879828Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.Type: GrantFiled: March 13, 2006Date of Patent: February 1, 2011Assignee: Wyeth LLCInventors: Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
-
Publication number: 20110021466Abstract: The disclosure provides a method of reducing infarct size in the heart following permanent ischemia or ischemia/reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof, wherein the subject is a human or a veterinary animal. Additionally the disclosure provides a method of treating subarachnoid hemorrhage or atrial fibrillation or of enhancing or preserving migration, seeding, proliferation, differentiation and/or survival of stem cells in injured heart tissue comprising administering a drug selected from the group consisting of epicatechin, derivatives thereof and pharmaceutically acceptable salts thereof. The effects of epicatechin administration are sustained over time.Type: ApplicationFiled: March 12, 2009Publication date: January 27, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Francisco Villarreal, Katrina Go Yamazaki, Pam Rajendran Taub, Alan Maisel
-
Publication number: 20110020414Abstract: An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one non-limiting illustration, the anti-aging composition contains about 1.0 vol % retinol, plantago lanceolata, hypericum perforatum leaf extract, phytosphingosine, leontopodium alpinum extract, glycyrriza glabra root extract, sambucus nigra flower extract, nordihydrognaiaretic acid, oleanolic acid, spiraea ulmaria flower extract, evodia rutaecarpa fruit extract, boswellia serrata extract, and additives.Type: ApplicationFiled: July 27, 2010Publication date: January 27, 2011Inventor: Audrey KUNIN
-
Publication number: 20110008306Abstract: The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject.Type: ApplicationFiled: February 2, 2010Publication date: January 13, 2011Inventor: Belinda Tsao NIVAGGIOLI
-
Publication number: 20110003776Abstract: This invention relates to tetrahydropyranonaphthyridines derivatives having formula (III) or IV: and analogues of the tetrahydropyranonaphthyridines derivatives. The invention also relates to pharmaceutical compositions comprising these compounds and methods for treatment of tuberculosis using these compounds.Type: ApplicationFiled: June 3, 2010Publication date: January 6, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: John K. Snyder, John A. Porco, JR., Ya Zhou
-
Publication number: 20100317629Abstract: A pharmaceutical implant may include a pharmaceutical and at least one excipient, and may be configured to be implanted in a body of a patient. The at least one excipient may dissolve after implantation of the pharmaceutical implant in the body of the patient and release the pharmaceutical. In some examples, the pharmaceutical implant includes at least two pharmaceuticals. The at least one excipient may be selected to provide a desired release profile of the pharmaceutical. For example, the pharmaceutical implant may be configured to dissolve and release the pharmaceutical over a length of time between about one day and about 30 days. In some examples, the pharmaceutical implant may be implanted in the body of the patient proximate to an implantable medical device.Type: ApplicationFiled: June 11, 2010Publication date: December 16, 2010Applicant: Medtronic, Inc.Inventors: Genevieve L. Gallagher, Kimberly Chaffin, Zhongping Yang
-
Publication number: 20100305065Abstract: There is provided the use of compounds of formula wherein R1, R2, R3 and E have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula (I) per se.Type: ApplicationFiled: May 16, 2008Publication date: December 2, 2010Applicant: HELPERBY THERAPEUTICS LIMITEDInventors: Mandy Christine Beswick, Susan Mary Cramp, Yanmin Hu, Thomas David Pallin, Hazel Joan Dyke, Anthony Coates
-
Publication number: 20100303799Abstract: Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.Type: ApplicationFiled: October 6, 2008Publication date: December 2, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Geert W. Schmid-Schönbein, Frank A. DeLano
-
Publication number: 20100305056Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, strongyloidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.Type: ApplicationFiled: November 26, 2008Publication date: December 2, 2010Applicant: Merck Frosst Canada Ltd.Inventors: Elise Isabel, Christophe Mellon, Christian Beaulieu
-
Publication number: 20100298278Abstract: The invention relates to the substituted 1,2-ethylenediamines of general formula (I), wherein the groups R1 to R13, A, B, L and i are defined as in the description and the claims. The invention also relates to the use thereof in the treatment of Alzheimer's disease (AD) and similar diseases.Type: ApplicationFiled: August 8, 2006Publication date: November 25, 2010Inventors: Christian Eickmeier, Klaus Fuchs, Niklas Heine, Stefan Peters, Cornelia Dorner-Ciossek, Sandra Handschuh, Herbert Nar, Klaus Klinder
-
Publication number: 20100291025Abstract: The present invention relates to new indazole inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 13, 2010Publication date: November 18, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20100291026Abstract: The present invention relates to new piperidine inhibitors of Janus kinase 3 activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 20, 2010Publication date: November 18, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20100285012Abstract: The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8).Type: ApplicationFiled: January 5, 2009Publication date: November 11, 2010Applicant: University of FLorida Research Foundation Inc.Inventors: William A. Dunn, JR., Debra E. Akin, Ann Progulske-Fox, David A. Ostrov
-
Publication number: 20100278894Abstract: An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer.Type: ApplicationFiled: March 16, 2010Publication date: November 4, 2010Inventor: Robert E. Burgmeier
-
Publication number: 20100278895Abstract: An antimicrobial accessory may include a polymer an antimicrobial mixed in the polymer, and an antioxidant. The antioxidant may include, for example, at least one of citric acid, maltol, kojic acid, malic acid, or vitamin A. In some examples, the antioxidant may include an ascorbate peroxidase in combination with ascorbic acid, a glutathione peroxidase in combination with glutathione, or a superoxide dismutase in combination with a metal such as Ni, Cu, Mn, or Fe. In some examples, the antimicrobial accessory may include at least three polymer layers. For example, the antimicrobial accessory may include a first layer comprising a biodegradable polymer and an antimicrobial. The antimicrobial accessory may further include a sacrificial diffusion layer formed on a surface of the first layer. The sacrificial diffusion layer may include a biodegradable polymer, which may be the same biodegradable polymer as in the first layer or may be a different biodegradable polymer.Type: ApplicationFiled: March 16, 2010Publication date: November 4, 2010Inventor: Robert E. Burgmeier
-
Publication number: 20100266540Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.Type: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Applicant: University of Kentucky Research FoundationInventor: Rolf Joseph CRAVEN
-
Publication number: 20100247600Abstract: A drug-eluting implant cover fabricated from a drug-eluting biocompatible matrix containing at least one elutable drug, a drug-eluting implant cover kit containing at least one drug-eluting implant cover, and a method of manufacturing the same.Type: ApplicationFiled: October 30, 2009Publication date: September 30, 2010Applicant: Warsaw Orthopedic, Inc.Inventors: Jusong Xia, Hai H. Trieu, William F. McKay, Newton H. Metcalf, JR., Nikolas F. Kerr, Drew Amery
-
Publication number: 20100247544Abstract: Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value.Type: ApplicationFiled: January 19, 2010Publication date: September 30, 2010Inventor: David John Vachon
-
Publication number: 20100240619Abstract: Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1 N-oxides, and salts thereof, wherein R1, R2, A, G, W, Z1, X, J, and n are as defined in the disclosure, and (b) at least one additional fungicidal compound. Also disclosed is a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of the aforesaid composition. Also disclosed is a composition comprising component (a) of aforesaid composition and at least one insecticide. Also disclosed are compounds of Formula 1A, 1B and 1C, wherein R1, R2, A, G, W, Z1, X, J, n, Z3, M and J1 are as defined in the disclosure.Type: ApplicationFiled: October 23, 2008Publication date: September 23, 2010Inventors: Vann Gregory, Robert James Pasteris
-
Publication number: 20100239523Abstract: The invention provides Toll-like receptor (TLR) modulators, compositions comprising the same, and methods for using the same.Type: ApplicationFiled: October 30, 2008Publication date: September 23, 2010Applicant: The Regents of the University of ColoradoInventors: Linda May Rothblum Watkins, Mark Rowland Hutchinson
-
Publication number: 20100227791Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.Type: ApplicationFiled: January 7, 2010Publication date: September 9, 2010Inventors: Gianfranco Peluso, Menotti Calvani